FDA pilots fast-track scheme for US-made generics скачать в хорошем качестве

FDA pilots fast-track scheme for US-made generics

In today’s headlines – 6 October: In another effort to boost domestic drug manufacturing, the FDA is piloting fast-track reviews for generics tested and made in US facilities. Edinburgh-based Trogenix has raised £70m to fund clinical trials of its triple-acting immunotherapies for brain and colorectal cancers. AstraZeneca and Daiichi Sankyo's Datroway comes good in the delayed TROPION-Breast02 trial as a frontline triple-negative breast cancer treatment. Oculis is poised to start registration trials for privosegtor, its drug candidate for neuro-ophthalmic diseases, in the wake of positive phase 2 data. Roche and Klinrisk have picked up a CE-mark for an AI tool that can be used to predict renal function decline in patients with chronic kidney disease. Subscribe to @Pharmaphorum for daily news updates and check out www.pharmaphorum.com for more insights and analysis. #news #pharma #pharmanews #pharmainnovation #pharmaindustry #lifesciences #biotechnews #biopharma #drugdevelopment #drugdiscovery #fda #fdaregulations #generics #trogenix #immunotherapy #colorectalcancer #braincancer #astrazeneca #daiichisankyo #breastcancer #oculis #roche #klinrisk #chronickidneydisease #ai #artificialintelligence As an official Frontiers Health conference partner, we are pleased to offer pharmaphorum readers an exclusive 20% discount. Don’t miss this unique opportunity to engage with some of the brightest minds in modern healthcare to discuss the biggest trends, opportunities, and challenges facing today’s health innovators. Click below and use promo code: FH25PHP20 to register at a reduced price: https://www.frontiers.health/2025-reg...